ERYTECH to Participate in
the Upcoming April Investor Conferences
Investor Access Event
Link to the event
- Date:
Monday, April 4 th andTuesday, April 5 th - Place:
Paris (France) - Participant: Eric SOYER (CFO-COO)
Kempen 14th
Link to the event
- Date:
Thursday, April 21 st - Place:
Amsterdam (Netherlands) - Participants: Gil BEYEN (CEO) and Eric SOYER (CFO-COO)
If you are interested in arranging a one-on-one meeting, please contact your conference representative.
About ERYTECH and eryaspase (GRASPA®)
ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.
The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cells’ altered asparagine and glutamine metabolism. The proof of concept of eryaspase as a cancer metabolism agent was established in different trials in acute lymphoblastic leukemia (ALL) and pancreatic cancer. An investigator sponsored Phase 2 trial (IST) evaluating the use of eryaspase in ALL patients who developed hypersensitivity reactions to pegylated asparaginase recently reported positive results, based on which the Company intends to request approval in
Eryaspase received Fast Track designation from the
ERYTECH produces its product candidates for treatment of patients in
ERYTECH is listed on the Nasdaq Global Select Market in
For more information, please visit www.erytech.com
CONTACTS
ERYTECH CFO & COO | NewCap Investor relations Nicolas Merigeau Media relations |
+33 4 78 74 44 38 investors@erytech.com | +33 1 44 71 94 94 erytech@newcap.eu |
Attachment
- 220328_ERYTECH_PR_
APR 2022 Investor Conf_EN_vf-2
© OMX, source